Browse > Article

Evaluation of Cancer Treatment Using FDG-PET  

Ryu, Jin-Sook (Department of Nuclear Medicine Asan Medical Center, University of Ulsan College of Medicine)
Publication Information
The Korean Journal of Nuclear Medicine / v.36, no.1, 2002 , pp. 64-73 More about this Journal
Abstract
FDG-PET has potential as an effective, non-invasive tool to measure tumor response to anticancer therapy. The changes in tumor FDG uptake may provide an early, sensitive guide to the clinical and subclinical response of tumors to cancer treatment, as well as functional assessment of residual viable tumor. This may allow the evaluation of subclinical response to anticancer drugs in early clinical trials and improvements in patients management. However, monitoring tumor responses with FDG-PET is still in its infancy. The methods of measurement of FDG uptake are currently diverse and timing with respect to anti cancer therapy variable. Therefore, there is a need for larger-scale trials along with standardized methodology and a collection of reproducibility data. The recent guideline from the European group seems to be the most comprehensive. In future, the combination of morphological and metabolic images may improve the quantitative nature of these measurements by relating tumor viability to total tumor mass. More data on sensitivity and specificity of FDG-PET technique are needed along with continued advancement of PET methodology.
Keywords
$^{18}F-fluorodeoxyglucose$; positron emission tomography; therapy response;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Dehdadashti F, Flanagan FL, Mortimer JE,Katzenellenbogen lA, Welch MJ, Siegel BA.Positron emission tomographic assessment of"metabolic flare" to predict response of metastaticbreast cancer to anti-estrogen therapy. Eur J NuclMed 1999, 26; 51-6.
2 Jansson T, Westlin JE, Ahlstrom H, Lilja A,Langstrom B, Bergh J. Positron emissiontomography studies in patients with locallyadvanced and/or metastatic breast cancer: a methodfor early therapy evaluation? J Clin Oneol1995;13:1470-7.
3 Findly M, Young H, Cunning D, et al. Noninvasivemonitoring of tumor metabolism usingfluorodeoxyglucose and positron emissiontomography in colorectal cancer liver metastasis;correlation with tumor response to fluorouracil. JClin Oneol 1996; 14: 700-8.
4 Spaepen K, Stroobants S, Dupont P, VanSteenweghen S, Thomas J, Vandenberghe P, et al.Prognostic value of positron emission tomography(PET) with fluorine-18 fluorodeoxyglucose(C8F]FDG) after first-line chemotherapy in nonHodgkin'slymphoma: is C8F]FDG-PET a validalternative to conventional diagnostic methods? JClin Oneol 2001;19:414-9.
5 Keyes JW. SUV: Standard uptake or silly useless value? J Nucl Med 1995;36:1836-9.
6 Yao WJ, Hoh C. Quantitation of tumor glucosemetabolism with FDG and PET. Ann Nucl Med1995;8:104-14.
7 Eckelman WC, Tatum JL, Kurdziel KA, Croft BY.Quantitative analysis of tumor biochemisty usingPET and SPECT. Nucl Med Bioi 2000;27:633-5.
8 van der Hiel B, Pauwels EK, Stokkel MP. Positronemission tomography with 2-[18F]-fluoro-2-deoxyD-glucose in oncology. Part lIla: Therapy responsemonitoring in breast cancer, Iymphma and gliomas.J Cancer Res Clin Oncol 2001;127:269-77.
9 Wahl RL, Zasadny K, Helvie M, Hutchins GD,Weber B, Cody R. Metabolic monitoring of breastcancer chemoradiotherapy using positron emissiontomography: initail evaluation. J Clin Oneol1993,11,2101-11.
10 Mortimer JE, Dehdashti F, Siegel BA, Trinkaus K,Katzenellenbogen JA, Welch MJ. Metabolic flare:indicator of hormone responsiveness in advancedbreast cancer. J Clin Oneol 2001;19:2797-803.
11 Kenneth R. Zasadny, richard L. Wahl. Standardizeduptake values of normal tissues at PET with2- [FI uorine-18] -FI uoro-2-deoxy- D- gl ucose:Variations with body weight and a method forcorrection. Radiology 1993;189-847-50.
12 Hautzel H, Muller-Gartner HW, Early changes in fluorine-18-FDG uptake during radiotherapy J Nucl Med 1997;38:1384-6.
13 Cermerius U, Fabry U, Kroll U, Zinmy M,Neuerburg J, Osieka R, et al. Clinical value ofFDG-PET for therapy monitoring of malignantlymphoma-results of retrospective study in 72patients. Nuklearmedizin 1999;38;24-30.
14 Young H, Baum R, Cremerius U, Herholz K,Hoekstra 0, Lammertsma AA, et al. Measurementof clinical and subclinical tumour response using[18F]-fluorodeoxyglucose and positron emissiontomography: Review and 1999 EORTCrecommendations. Eur J Cancer 1999;35:1773-82.
15 Hoekstra CJ, Paglianiti I, Hoekstra OS, Smit EF,Postmus PE, Teule GJJ, et al. Monitoring responseto therapy in cancer using [18F]-2-fluoro-2-deoxyD-glucose and positron emission tomography: anoverview of different analytical methods. Eur JNucl Med 2000;27:731-43.
16 Ogawa T, Uemura K, Shishido F, Yamaguchi T,Murakami M, Inugami A, et al. Changes ofcerebral blood flow, and oxygen and glucosemetabolism following radiochemotherapy of glioma;a PET study. J Comp Assist Tomogr 1988;12:290-7.
17 lchiya Y, Kuwabara Y, Otsuka M, Tahara T, Yoshikai T, Fukumura T, et al. Assessment of response to cancer therapy using fluorine-18fluorodeoxyglucose and positron emission tomography. J Nucl Med 1991; 32:1655-60.
18 Stokkel MP, Draisma A, Pauwels EK. Positronemission tomography with 2-[18F]-fluoro-2-deoxyD-glucose in oncology. Part IlIb: Therapy responsemonitoring in colorectal and lung tumours, head andneck cancer, hepatocellular carcinoma and sarcoma.J Cancer Res Clin Oncol 2001;127:278-85.
19 Oosterom AT, Judson I, Verweij J, Stroobants S,Paola ED, Dimitrijevic S, et al. Safety and efficacyof imatinb(STI571) in metastatic gastrointestinalstromal tumors; a phase I study. Lancet 2001;358:1421-3.
20 Zinzani PL, Magagnoli M, Chierichetti F,Zompatori M, Garraffa G, Bendandi M, et al. Therole of positron emission tomography (PET) in themanagement of lymphoma patients. Ann Oneol1999;10: 1181-4.
21 Brucher BL, Weber W, Bauer M, Fink U, Avril N,Stein HJ, et al. Neoadjuvant therapy of esophagealsquamous cell carcinoma: response evaluation bypositron emission tomography. Ann Surg 2001;233:300-9.
22 Brock CS, Young H, O'Reilly SM, Matthews J,Osman S, Evans H, et al. Early evaluation of tumourmetabolic response using[18F]fluorodeoxyglucose andpositron emission tomography; a pilot studyfollowing the phase I1 chemotherapy schedule fortemozolomide in recurrent high -rade gliomas. Br JCancer 2000;8:608-15.
23 Bassa P, Kim EE, Inoue T, Wong FC, Korkmaz M,Yang DJ, et al. Evaluation of preoperativechemotherapy using PET with fluorine18-fluorodeoxyglucose in breast cancer. J Nucl Med1996; 37:931-8.
24 Ryu JS, Choi NC, Fischman AJ, lynch TJ, MathisenDJ; FDG-PET instaging and restaging non-smallcell lung cancer after neoajuvant chemoradiotherapy:correlation with histopathology. Lung Cancer 2002,35;179-87.
25 De Santis M, Bokemeyer C, Becherer A, Stoiber F,Oechsle K, Kletter K, et al. Predictive impact of2-18fluoro-2-deoxy-D-glucose positron emissiontomography for residual postchemotherapy massesin patients with bulky seminoma. J Clin Oneol2001;19:3740-4.
26 Husband J, MacVicar D. Assessment of response totreatment and dectection of relapse. In: HusbandJES, Rezenek RH, editors. Imaging in oncology.Oxford: Isis Medical Media Ltd.: 1998. P.899-924.
27 Rigo P, Paulus P, Kaschten BJ, Hustinx R, Bury T,Jerusalem G, et al. Oncological applications ofpositron emission tomography with fluorine-18fluorodexy-glucose. Eur J Nucl Med 1996;23:1641-74.
28 Mankoff DA, Bellon JR. Positron-emissiontomographic imaging of cancer: glucose metabolismand beyond. Semin Radiat Oncol 2001;11:16-27.
29 Brock CS, Meikle SR, Price P. Dose fluorine-18fluorodeoxy-glucose metabolic imaging of tumoursbenefit oncology? Eur J Nucl Med 1997;24;691-705.
30 Weber WA, Ott K, Becker K, DitHer HJ,Helmberger H, Avril NE, et al. Prediction ofresponse to preoperative chemotherapy inadenocarcinomas of the esophagogastric junction bymetabolic imaging. J Clin Oneal 2001;19:3058-65
31 Burcombe RJ, Makris A, Pittam M, Lowe J,Emmott J, Wong WL. Evaluation of good clinicalreponse to neoadjuvant chemotherapy in primarybreast cancer using [18F]-fluorodeoxyglucosepositron emission tomograpy. Eur J Cancer,2002;38:375-9.
32 Harberkorn U, Strauss LG, Dimitrakopoulou A, etal. PET studies of fluorodeoxy glucose metabolismin patients with recurrent colorectal tumors receivingradiotherapy. J Nucl Med 1991;32: 1485-90.
33 Wiedmann E, Baican B, Hertel A, Baum RP, ChowKU, Knupp B, et al: Positron emissiontomography(PET) for stagng and evaluatiion ofresponse to treatment in patients with Hodgkin'sdisease. Leuk Lymphoma 1999;34:545-51.
34 Weber WA, Schwaiger M, Avril N. Quantitativeassessment of tumor metabolism using FDG-PETimaging. Nucl Med Bioi 2000;27:683-7.
35 Haberkorn U. Strauss LG. Dimitrakopoulou A.Seiffert E. Oberdorfer F. Ziegler S. et al.Fluordeoxyglucose imaging of advanced head andneck cancer after chemotherapy. J Nucl Med1993;34:12-7.
36 Vansteekiste JF, Stroobants SG, Dupont PJ, DeLeyn PR, Verbeken EK, Deneffe GJ, et al.Prognostic importance of the standardized uptakevalue on 18F-fluoro-2-deoxy-glucose-positron emissiontomography scan in non-small-cell lung cancer; ananalysis of 125 cases. J Clin Oneol 1999; 7:3201-6.
37 van Ginkel RJ, Hoekstra HJ, Pruim J, Nieweg OE,Molenaar WM, Paans AM, et al. FDG-PET toevaluate responses to hyperthermic isolated limbperfusion for locally advanced soft tissue sarcoma.J Nucl Med 1996;37: 984-90.